Analysts Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $58.55

Tempus AI, Inc. (NASDAQ:TEM) has received an average rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $58.55.

Several equities analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Bank of America lifted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. TD Cowen reaffirmed a “buy” rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th.

Insiders Place Their Bets

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James William Rogers sold 31,780 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40. Following the completion of the sale, the chief financial officer now directly owns 189,320 shares in the company, valued at approximately $15,586,715.60. This represents a 14.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,583,467 shares of company stock valued at $130,542,311 in the last ninety days.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Tempus AI in the 4th quarter valued at $108,000. Voloridge Investment Management LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at $11,826,000. Two Sigma Advisers LP bought a new stake in shares of Tempus AI in the 4th quarter valued at $625,000. ProShare Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at $244,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Tempus AI during the 4th quarter valued at $1,034,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Stock Down 11.2 %

Shares of NASDAQ:TEM opened at $68.09 on Wednesday. The firm has a 50 day moving average of $50.29 and a 200-day moving average of $51.65. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 12 month low of $22.89 and a 12 month high of $91.45.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.